Navigation Sciences is focused on advancing surgical techniques for the treatment of soft tissue cancers, particularly through its innovative NaviSci™ system. This system is designed to provide real-time GPS navigation and precise margin control during surgeries, which is crucial for effectively locating and removing lung and other soft tissue cancers. The technology aims to enhance surgical outcomes by reducing the risk of early-stage cancer recurrence, conserving lung function, improving surgical workflow, and shortening hospital stays. The NaviSci system has already completed a clinical feasibility trial, indicating its potential impact in the field of precision cancer surgery.

The leadership team at Navigation Sciences comprises experts in thoracic surgery and advanced surgical navigation technology, including Dr. Raphael Bueno and Dr. Jayender Jagadeesan, who are affiliated with Brigham and Women’s Hospital and Harvard Medical School. Their combined expertise in surgical navigation, image-guided therapy, and minimally invasive surgical devices underpins the development of the NaviSci system. The company has also been recognized for its innovative approach, having been selected as a 'Best Start-up' candidate by the Prix Galien Foundation, and has secured key patents to protect its technology, further solidifying its position in the medical technology landscape.

United States

Navigation Sciences™ is a clinical-stage company developing the NaviSci™ System for the tissue conserving removal of lung cancer and other soft tissue tumors. The system integrates Augmented Reality (AR) and advanced software with surgical instruments to guide precise surgical resection by enabling for the first time, real-time in-vivo margin measurement. The system aims to improve surgical outcomes with cutting-edge technologies that – reduce recurrence risk and conserve lung function – shorten hospital length of stay and enhance surgical workflow.

Navigation Sciences

Company Details